Insiders Celltrion, Inc.

Equities

End-of-day quote Korea S.E. Other stock markets 05/12/2025			5-day change	1st Jan Change
183,300.00 ^KRW	+0.38%		-1.03%	+1.67%

12-03	Celltrion Announces U.S. FDA Approval of 300mg strength of OMLYCLO®?	CI
11-28	Celltrion, Inc. Receives Health Canada Approval for Eydenzelt®?, a Biosimilar Confirming Eylea®? (aflibercept 2Mg)	CI

Celltrion Group Creator Expected to Resume Leadership Role	07/03/23	MT
Celltrion, Inc.'s Equity Buyback announced on May 18, 2022, has closed with 500,000 shares, representing 0.36% for KRW 78,411.31 million.	21/07/22	CI

No results for this search